dc.contributor.author | Fleischhacker, Tenille | |
dc.date.accessioned | 2017-09-15T15:18:36Z | |
dc.date.available | 2017-09-15T15:18:36Z | |
dc.date.issued | 2017-09-15T15:18:36Z | |
dc.identifier.uri | http://hdl.handle.net/10222/73315 | |
dc.description.abstract | Familial exudative vitreoretinopathy (FEVR) is a blinding disorder that results in incomplete peripheral retinal vascularization at birth and there is currently no treatment. Zebrafish were used as a model to mimic a FEVR-like phenotype in order to carry out a preliminary drug screen for novel therapeutic compounds. A novel FEVR gene, cdh5, was knocked down using morpholino oligonucleotide and displayed a robust retinal phenotype and smaller eye size. Sphinghosine-1 phosphate receptor-2 (S1PR2) is a known inhibitor of blood vessel development. Several compounds predicted to interact with S1PR2 were screened using the cdh5 morphant zebrafish including an S1PR2 inhibitor; JTE-013. JTE-013 significantly improved eye size establishing that S1PR2 can be targeted in zebrafish. “Compound 1” significantly decreased eye size, whereas “compound 2” had no effect. Thus, S1PR2 is a possible pharmacological target for the treatment of FEVR. | en_US |
dc.language.iso | en | en_US |
dc.subject | zebrafish | en_US |
dc.subject | FEVR | en_US |
dc.subject | vitreoretinopathy | en_US |
dc.title | UTILIZING ZEBRAFISH TO MODEL THE CHILDHOOD BLINDING DISORDER, FAMILIAL EXUDATIVE VITREORETINOPATHY (FEVR), AND DISCOVER NOVEL THERAPEUTICS | en_US |
dc.date.defence | 2016-08-04 | |
dc.contributor.department | Department of Clinical Vision Science | en_US |
dc.contributor.degree | Master of Science | en_US |
dc.contributor.external-examiner | Dr. William Baldridge | en_US |
dc.contributor.graduate-coordinator | Darren Oystreck | en_US |
dc.contributor.thesis-reader | Dr. Christopher McMaster | en_US |
dc.contributor.thesis-reader | Dr. Shelby Steele | en_US |
dc.contributor.thesis-supervisor | Dr. Johane Robitaille | en_US |
dc.contributor.thesis-supervisor | Dr. Jason Berman | en_US |
dc.contributor.ethics-approval | Received | en_US |
dc.contributor.manuscripts | No | en_US |
dc.contributor.copyright-release | Yes | en_US |